Biosimilars Conference 2012

Following the success of our past events, SMi’s third Biosimilars and Biobetters conference will build upon the progress made in previous meetings and further develop the ideas and strategies that were debated and discussed. In particular how industry players will face regulatory challenges in approval of follow on biologics, rising development costs, threat from competition and a similar if not bigger challenge to that seen in marketing of innovator drugs.
There will be case studies from those who are both developing and distributing follow on biologics. With analysis of key trends in biologic pipelines, methods in clinical trials for biosimilar approval, a review of emerging markets, assessment of biosimilar manufacturing, post approval strategy and future forecasting for follow on biologics.